Substance / Medication

Galantamine

Overview

Active Ingredient
galantamine
RxNorm CUI
4637

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review.
Xing Bingke, Yang Jingran, Hua Hui et al. · Medicine (Baltimore) · 2025
PMID: 40489822Meta-AnalysisFull text (PMC)
Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
Lim Amanda Wei Yin, Schneider Lon, Loy Clement · Cochrane Database Syst Rev · 2024
PMID: 39498781Meta-AnalysisFull text (PMC)
Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement.
Koola Maju Mathew, Looney Stephen W, Hong Houlin et al. · Psychiatry Res · 2020
PMID: 32763546Meta-Analysis
Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Jiang Deqi, Yang Xiujuan, Li Mingxing et al. · J Neural Transm (Vienna) · 2015
PMID: 25547862Meta-Analysis
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo Simona Gabriella, Prinelli Federica, Adorni Fulvio et al. · J Alzheimers Dis · 2013
PMID: 23411693Meta-Analysis
Galantamine and behavior in Alzheimer disease: analysis of four trials.
Kavanagh S, Gaudig M, Van Baelen B et al. · Acta Neurol Scand · 2011
PMID: 21615354Meta-Analysis
Analyses of mortality risk in patients with dementia treated with galantamine.
Feldman H H, Pirttila T, Dartigues J F et al. · Acta Neurol Scand · 2009
PMID: 18518863Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Galantamine (substance)
SNOMED CT
395727007
UMLS CUI
C0016967
RxNorm CUI
4637

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.